Reference
Reference TypeLiterature
TitleGRIK2 is a target for bladder cancer stem-like cell-targeting immunotherapy.
AuthorsHaruka Miyata; Yoshihiko Hirohashi; Shuhei Yamada; Junko Yanagawa; Aiko Murai; Shinichi Hashimoto; Serina Tokita; Kanta Hori; Takashige Abe; Terufumi Kubo; Tomohide Tsukahara; Takayuki Kanaseki; Nobuo Shinohara; Toshihiko Torigoe
AffiliationsDepartment of Pathology, Sapporo Medical University School of Medicine, South-1 West-17, Chuo-Ku, Sapporo, Hokkaido, 060-8556, Japan; Department of Renal and Genitourinary Surgery, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido, 060-8648, Japan; Department of Pathology, Sapporo Medical University School of Medicine, South-1 West-17, Chuo-Ku, Sapporo, Hokkaido, 060-8556, Japan. hirohash@sapmed.ac.jp; Department of Molecular Pathophysiology, Institute of Advanced Medicine, Wakayama Medical University, Wakayama, Wakayama, 641-8509, Japan; Department of Pathology, Sapporo Medical University School of Medicine, South-1 West-17, Chuo-Ku, Sapporo, Hokkaido, 060-8556, Japan. torigoe@sapmed.ac.jp.
JournalCancer Immunol Immunother
Year2022
AbstractRecent studies have revealed that treatment-resistant cancer stem-like cells (CSCs)/cancer-initiating cells (CICs) can be targeted by cytotoxic T lymphocytes (CTLs). CTLs recognize antigenic peptides derived from tumor-associated antigens; thus, the identification of tumor-associated antigens expressed by CSCs/CICs is essential. Human leucocyte antigen (HLA) ligandome analysis using mass spectrometry enables the analysis of naturally expressed antigenic peptides; however, HLA ligandome analysis requires a large number of cells and is challenging for CSCs/CICs. In this study, we established a novel bladder CSC/CIC model from a bladder cancer cell line (UM-UC-3 cells) using an ALDEFLUOR assay. CSCs/CICs were isolated as aldehyde dehydrogenase (ALDH)-high cells and several ALDH<sup>high</sup> clone cells were established. ALDH<sup>high</sup> clone cells were enriched with CSCs/CICs by sphere formation and tumorigenicity in immunodeficient mice. HLA ligandome analysis and cap analysis of gene expression using ALDH<sup>high</sup> clone cells revealed a distinctive antigenic peptide repertoire in bladder CSCs/CICs, and we found that a glutamate receptor, ionotropic, kainite 2 (GRIK2)-derived antigenic peptide (LMYDAVHVV) was specifically expressed by CSCs/CICs. A GRIK2 peptide-specific CTL clone recognized GRIK2-overexpressing UM-UC-3 cells and ALDH<sup>high</sup> clone cells, indicating that GRIK2 peptide can be a novel target for bladder CSC/CIC-targeting immunotherapy.
Curation Last Updated2025-02-11 01:43:55
Epitope
Epitope ID722460
Chemical TypeLinear peptide
Linear SequenceRLQQLQHRV
Source Molecule NameATP-dependent DNA helicase DDX11
Source OrganismHomo sapiens (human)
Starting Position143
Ending Position151
Epitope Reference Details
Epitope Structure DefinesExact Epitope
Epitope NameRLQQLQHRV
Location of Data in ReferenceTable S2
In Vivo Processing
Host OrganismHomo sapiens (human)
In Vivo Process
In Vivo Process TypeOccurrence of cancer
Disease Stateurinary bladder cancer
Disease StageUnknown;
MHC Ligand Assay
Qualitative MeasurementPositive
Method/Techniquecellular MHC/mass spectrometry
Measurement ofligand presentation
Antigen Presenting Cells
Cell Tissue TypeBladder
Cell TypeEpithelial cell
Cell Culture ConditionsCell Line / Clone
MHC Allele
MHC Allele NameHLA-A2
MHC Evidence CodeElution with MHC specific antibody - BB7.2
MHC Ligand
Epitope RelationEpitope
Chemical TypeLinear peptide
Linear SequenceRLQQLQHRV
Source Molecule NameATP-dependent DNA helicase DDX11
Source OrganismHomo sapiens (human)
Starting Position143
Ending Position151
Assay Reference Details
Assay Comments by IEDB CuratorThe epitope was eluted from aldehyde dehydrogenase (ALDH) low UM-UC-3 L-3 bladder cancer cells.
Location of Assay Data in ReferenceTable S2